Introduction
Under physiologic conditions, anaplastic lymphoma kinase (ALK) tyrosine kinase is expressed in postnatal life seemingly exclusively by cells of neural origin. Its aberrant expression identified in a subset of T-cell lymphomas (ALK þ TCL) and other malignancies typically results from chromosomal translocations involving the ALK gene and various partner genes (Wasik, 2002) . The t(2;5)(p23;q35) translocation that occurs in >80% of ALK þ TCL fuses a distal portion of the ALK gene with the proximal part of the nucleophosmin (NPM) gene (Morris et al., 1994; Shiota et al., 1994) . The chimeric NPM/ALK protein is constitutively active due to autophosphorylation and promotes malignant cell transformation as shown both in vitro (Fujimoto et al., 1996; Bischof et al., 1997) and in vivo (Kuefer et al., 1997) by phosphorylating and activating signaling transmitters and pathways, such as phospholipase C (PLC)gphosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), Stat3, Stat5 and mitogen-induced extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) (Wasik, 2002; Marzec et al., 2007) .
Mammalian target of rapamycin (mTOR) is a ubiquitously expressed serine/threonine kinase that affects a number of key cell functions including protein synthesis and cell proliferation (Hay and Sonenberg, 2004; Shaw and Cantley, 2006) . mTOR associates with either protein called raptor or another named rictor. At present, the function of the mTOR-raptor complex is much better characterized (Hara et al., 2002) . The raptor-associated mTOR acts by directly activating p70S6 kinase 1 (p70S6K1) and inhibiting 4E-binding protein 1 (4E-BP1). In turn, p70S6K1 phosphorylates a S6 protein of the 40S ribosomal subunit (S6rp) at several sites including serines 235 and 236. The exact mechanisms of mTOR activation are still under investigation but at least two distinct signals are required. Whereas the first is provided by the cell membrane receptors for growth factors, such as insulin, the second is generated by nutrients (Takano et al., 2001; Peng et al., 2002) . The receptors activate cell-signaling pathways PI3K/Akt (Brunn et al., 1996; Sekulic et al., 2000) and ERK/ MEK (Tee et al., 2003; Roux et al., 2004; Ma et al., 2005 ) that indirectly activate mTOR by suppressing activity of tuberous sclerosis complex proteins TSC1 and TSC2 that, in turn, inhibit activity of mTOR through inactivating the G protein Rheb. mTOR can be functionally impaired by inhibitors from the rapamycin family. Rather than occupying the kinase and ATPbinding domain, rapamycin-type drugs block the binding of rapamycin to the FKBP12 protein and, consequently, inhibit enzymatic activity of the mTORraptor complexes. Rapamycin and its derivatives are currently used clinically as immunosuppressive drugs and evaluated as therapeutic agents in various types of cancer.
Results
Persistent activation of mTOR signaling pathway in ALK þ TCL cells is serum growth factor independent and nutrient dependent To evaluate the mTOR pathway in ALK þ TCL, we examined four ALK þ TCL-derived cell lines that preserved key characteristics of the native malignant T cells (Zhang et al., 2002) . We also tested three ALKÀTCL cell lines that share with the ALK þ TCL many characteristics including anaplastic cell morphology and CD30 antigen expression (Zhang et al., 1996) . As controls we used the Epstein-Barr virus-transformed (EBV) þ and EBVÀ B-cell lines, all of which show persistent activation of the mTOR pathway, but only the former display simultaneous activation of the PI3K/ Akt pathway . All four ALK þ TCL lines showed activation of the mTOR pathway as determined by phosphorylation of the mTOR targets S6rp and 4E-BP1 ( Figure 1a ). As expected (Slupianek et al., 2001) , ALK þ TCL cells displayed phosphorylation of Akt. This phosphorylation was, however, much weaker than in control EBV þ B cells. Similarly, the relatively weak phosphorylation of TSC2 at serine 939 that is targeted by Akt (Manning et al., 2002) was also noted. All ALKÀTCL also displayed activation of the mTOR pathway and relatively weak activation of the PI3K/Akt pathway.
We next examined the effect of serum and nutrient deprivation on mTOR activation in ALK þ TCL cells. mTOR activation was not affected by overnight serum withdrawal but was abrogated by the brief depletion of nutrients ( Figure 1b) . mTOR inhibition was reversed by cell re-exposure to the complete, nutrient-containing medium. To provide direct evidence that the growth factor and nutrient deprivation did not induce massive cell death, we examined propidium iodide (PI) uptake by the nutrient-and growth factor-depleted ALK þ TCL cells (Figure 1c ). Overnight culture of cells in fetal bovine serum (FBS)-free medium and an additional 2-h culture in FBS/nutrient-free medium induced only a limited increase in the cell death rate (0.42 and 1.2%, respectively, compared with 0.05% for control cells). Finally, to demonstrate that activation of the mTOR pathway is not limited in ALK þ TCL to cultured cell lines, we examined primary lymphoma tissues from 12 ALK þ TCL patients. In all cases, the malignant ALK þ TCL cells strongly expressed phospho-S6rp and phospho-4E-BP1 (Figure 1d ; representative results).
Activation of mTOR pathway in ALK þ TCL depends on expression and activity of NPM/ALK We asked next whether NPM/ALK played a role in mTOR activation. First, we examined activation of the mTOR pathway in the lymphoid, growth factor (interleukin (IL)-3)-dependent BaF3 cell line stably transfected with a vector containing NPM/ALK (wild-type or kinase-deficient K210R mutant) or an empty vector. Whereas the NPM/ALK-and empty vector-carrying BaF3 cells displayed phosphorylation of S6rp and 4E-BP1 upon exposure to IL-3, only the wild-type NPM/ ALK-transfected cells maintained phosphorylation after IL-3 withdrawal ( Figure 2a) . Next, we depleted NPM/ALK by small interfering RNA (siRNA) in ALK þ TCL-derived Karpas299 cells (Figure 2b ). Cells treated with ALK specific but not control, non-targeting siRNA displayed not only marked decrease in NPM/ ALK expression but also simultaneous inhibition of mTOR activation as determined by the greatly diminished phosphorylation of S6rp and 4E-BP1. Finally, to document that mTOR activation depends on the enzymatic activity of NPM/ALK, we treated ALK þ TCL cells with a small-molecule ALK inhibitor, WHI-P154, recently identified by us . As shown in Figure 2c , the compound profoundly suppressed phosphorylation of not only NPM/ALK but also Akt, TSC2, S6rp and 4E-BP1.
NPM/ALK-induced activation of mTOR is transduced preferentially by the MEK/ERK signaling pathway compared with the PI3K/Akt pathway As the PI3K/Akt pathway has been implicated in activation of mTOR signaling in other cell types (Brunn et al., 1996; Sekulic et al., 2000) , we examined next whether the pathway is involved in mTOR activation induced by NPM/ALK. We employed wortmannin that effectively inhibits PI3K at low nanomolar doses (Burgering and Coffer, 1995; Wlodarski et al., 2005) . As shown in Figure 3a , Akt activation was totally inhibited in NPM/ALK-transfected BaF3 cells with 1 nM of wortmannin. In contrast, activation of mTOR as determined by S6rp and 4E-BP1 phosphorylation was only mildly affected by 1 as well as 10 nM of the compound. Only when wortmannin was used at 200 nM was it able to inhibit mTOR activation, most likely through a direct inhibition of the kinase ). An essentially identical differential effect of wortmannin was also seen in ALK þ TCL cells ( Figure 3b) ; whereas 1 nM completely inhibited Akt phosphorylation, it induced only a weak inhibition of mTOR signaling. When used at 200 nM, wortmannin suppressed also mTOR activity. Reminiscent of wortmannin, Akt inhibitor III partially suppressed Akt phosphorylation when used at 1 and 10 mM, but had a barely appreciable impact on mTOR activity. Notably, when used at the PI3K/Akt inhibitory dose of 1 nM, wortmannin displayed no antiproliferative (Figure 3c and only a weak pro-apoptotic effect (Figure 3d ) on ALK þ TCL cells.
As the MEK/ERK signaling pathway is induced by NPM/ALK (Marzec et al., 2007) and can activate mTOR (Tee et al., 2003; Roux et al., 2004; Ma et al., 2005; Arvisais et al., 2006) , we examined whether inhibition of MEK would impact mTOR activation in ALK þ TCL cells. Treatment of Sudhl-1 cells with two different MEK inhibitors, U0126 and PD98059, markedly suppressed phosphorylation of not only ERK1/2 but also the mTOR target S6rp (Figure 4a ). The suppressive effect of MEK inhibition on mTOR activity was much stronger than the effect of PI3K inhibition, because separate application of the PI3K inhibitor wortmannin and U0126 in the same experiments yielded profound suppression of S6rp phosphorylation by the latter and weak inhibition by the former (Figure 4b) . Notably, administration of the inhibitors in combination further suppressed S6rp phosphorylation, indicating that the PI3K/Akt and MEK/ERK pathways regulate mTOR activation mostly independently of each other.
As MEK/ERK was found to act on mTOR by phosphorylating TSC2 (Tee et al., 2003; Roux et al., 2004; Ma et al., 2005; Arvisais et al., 2006) , we tested the impact of MEK inhibition on TSC2 phosphorylation. In addition to serine 939, the target of Akt (Manning et al., 2002) and possibly other kinases, we evaluated serine 1798 targeted by the ERK1/2 complex (Tee et al., 2003; Roux et al., 2004 U0126 and PD98059 had no appreciable effect on TSC2 phosphorylation on serine 939, they profoundly inhibited serine 1798 phosphorylation (Figure 4c ). To demonstrate that MEK activates mTOR pathway via the ERK1/2 complex, we depleted both ERKs by siRNA (Figure 4d ). The depletion of either ERK1 or ERK2 markedly diminished phosphorylation of the mTOR target S6rp (Figure 4d ).
Rapamycin-mediated inhibition of mTOR enzymatic activity impairs proliferation and survival of ALK þ TCL cells
To demonstrate that mTOR can be efficiently inhibited in ALK þ TCL cells by the mTOR inhibitor, we analysed the effect of rapamycin on mTOR signaling. Rapamycin used at 5 nM abrogated phosphorylation of S6rp and 4E-BP1 in two ALK þ TCL cell lines, indicating high sensitivity of these cells to the drug (Figure 5a ). To determine biological importance of the mTOR pathway, we examined proliferation and viability of four ALK þ TCL cell lines in response to rapamycin. As shown in Figure 5b , 5 nM of the drug profoundly (50-85%) suppressed proliferation of ALK þ TCL cells. The compound also markedly (75-300%) increased the apoptotic rate of the cells (Figure 5c ).
Discussion
It is very well established that NPM/ALK transforms T lymphocytes and other cells by persistently activating cell signaling pathways. However, relatively few NPM/ ALK-triggered pathways have been identified so far, with the roles of PI3K/Akt, STAT3, STAT5 and MEK/ ERK being the best characterized (Wasik, 2002; Chiarle et al., 2005; Kasprzycka et al., 2006; Marzec et al., 2007) . In this report, we provide several lines of evidence that NPM/ALK induces also activation of mTOR by the mechanisms schematically depicted in Figure 6 . NPM/ALK-induced mTOR activation requires nutrients as the second, independent signal. The NPM/ALKgenerated signal is transmitted through the MEK/ERK and, to a much lesser degree, the PI3K/Akt pathways. The mTOR inhibitor rapamycin profoundly suppresses proliferation and enhances the apoptotic rate of ALK þ TCL cells. These findings identify activation of the rapamycin-sensitive mTOR signaling pathway as a new mechanism by which NPM/ALK promotes malignant transformation. Furthermore, these data suggest that mTOR represents an attractive therapeutic target in ALK-induced malignancies. Whereas the mTOR pathway is persistently activated in many types of cancer, the exact stimuli that lead to the activation in both normal and transformed cells remain poorly defined. Two distinct signals are required for activation of the kinase, with one coming from growth factors and the second from nutrients (Hay and Sonenberg, 2004) . Although insulin represents the best characterized factor, a few other mTOR stimulators have been recently described. Accordingly, such diverse cell surface receptors and receptor ligands as CD40 (Sakata et al., 1999) , polycystein-1 (Shillingford et al., 2006) and prostaglandin F2a (Arvisais et al., 2006) can also activate mTOR. Based on our findings we can now add NPM/ALK to this expanding list. It may be relevant in this context that the structural relationship of ALK to the insulin receptor family (Morris et al., 1994; Shiota et al., 1994) might explain the ability of NPM/ALK to activate mTOR. In agreement with this hypothesis is the identification of MEK/ERK activation in neural cells transfected with ALK (Souttou et al., 2001) or stimulated through endogenous ALK (Motegi et al., 2004) . Furthermore, these observations suggest that, in addition to NPM/ALK, the full-length ALK and possibly other ALK hybrid proteins might activate mTOR.
Notably, we have documented that mTOR activation in ALK þ TCL cells is strictly nutrient dependent. This indicates that NPM/ALK-transformed cells retained the need for the second mTOR-activating signal that seemingly acts by directly targeting Rheb (Smith et al., 2005) . Recently, the hVps34 class III PI3K kinase family has been identified as the nutrient-activated intermediary involved in mTOR activation (Byfield et al., 2005; Nobukuni et al., 2005) . This observation raises the interesting question of whether hVps34 represents a novel therapeutic target in mTOR-dependent malignancies.
Although originally postulated to be the key activator of mTOR (Brunn et al., 1996; Sekulic et al., 2000) , over time the critical role of the PI3K/Akt pathway became 5nM Rapamycin (-) 5nM Rapamycin Figure 5 Inhibition of mTOR activity suppresses proliferation and decreases viability of ALK þ TCL cells. (a) ALK þ TCLderived Karpas299 and Sudhl-1 cell lines were cultured for 1 h with rapamycin at 5 nM or its solvent and analysed for phosphorylation of mTOR targets S6rp and 4E-BP1 using the other depicted phosphoproteins as controls. Separately, the four listed ALK þ TCL cell lines cultured in medium containing 5 nM of rapamycin or solvent alone, were examined for the proliferative (b) and apoptotic (c) cell rate.
less certain in at least some cell types. Accordingly, Aktmediated TCS phosphorylation is not critical for mTOR activity during Drosophila development (Dong and Pan, 2004) . Furthermore, at least two different ligands -TSH acting on thyroid epithelial cells (Suh et al., 2003) and prostaglandin F2a in luteal cells (Arvisais et al., 2006) can activate mTOR without exerting any appreciable effect on Akt. Finally, in transformed B lymphocytes mTOR activation is mostly, if not completely, PI3K/ Akt-independent . Our current results suggest that PI3K/Akt plays a rather limited role in mTOR activation in the ALK þ TCL cells, supporting the notion that other pathways trigger mTOR signaling. As we have found, the MEK/ERK pathway activates mTOR in ALK þ TCL cells and it does so more strongly than PI3K/Akt. A recent study (Vega et al., 2006) identified mTOR activation in ALK þ TCL and implicated Akt in the process. Our findings not only demonstrate that mTOR activation is triggered by NPM/ALK and that nutrients are required as the second signal for the mTOR activation in the ALK þ TCL cells but also, as discussed above, indicate that the contribution of PI3K/Akt to mTOR activation is relatively limited in such cells, in particular when compared with the MEK/ERK pathway. Reliance on the PI3K inhibitor LY294002, which seemingly inhibits mTOR at the equimolar concentration (Sabatini et al., 1994; Wlodarski et al., 2005) , sometimes results in overestimation of the contribution of the PI3K/Akt pathway to mTOR activation. Our findings suggest that mTOR represents a potential novel therapeutic target in NPM/ALK-expressing ALK þ TCL and, in all likelihood, other ALKdriven malignancies. Our previous studies indicate that mTOR inhibitors hold promise as potential therapeutic agents in other types of lymphoma (Zhang et al., 1996; Wlodarski et al., 2005) , with the effect on EBVtransformed B lymphocytes being the best documented (Majewski et al., 2000 (Majewski et al., , 2003 . Considering that mTOR inhibitors rapamycin and RAD001 are used as immunosuppressive drugs known to affect primarily T lymphocytes, ALK þ TCL cells may be quite sensitive to therapies targeting mTOR. Although it could be argued that NPM/ALK itself represents an attractive therapeutic target (Marzec et al., 2007) , combination of an ALK inhibitor with inhibitor(s) of its key effectors such as mTOR may be even more effective. Finally, given the strong antiproliferative and proapoptotic effect of rapamycin on ALK þ TCL cells (Figure 5 ), targeting mTOR alone may have a significant therapeutic effect in ALK þ TCL patients.
Materials and methods
ALK þ TCL, ALK-TCL, B-cell (BCL) and BaF3 cell lines NPM/ALK-expressing Sudhl-1, JB6, Sup-M2 and Karpas299 cell lines were derived from ALK þ TCL (Zhang et al., 2002; Marzec et al., 2005) . PB-1, 2A and 2B cell lines were developed from a progressive, skin-based T-cell lymphoma (Zhang et al., 1996) . The control EBV-negative Val and Ly18 and EBV þ lymphoblastoid B-cell lines (MM and HH) were described previously . The IL-3-dependent B-cell line BaF3 was transfected with an empty vector or vector containing NPM/ALK wild-type or K210R kinase-deficient mutant (Slupianek et al., 2001; Zhang et al., 2002) .
Kinase inhibitors WHI-P154 (Calbiochem, San Diego, CA, USA), identified by us to inhibit ALK , and PI3K inhibitor wortmannin were obtained from Calbiochem. U0126 (Promega, Madison, WI, USA) and PD98059 (Novagen, San Diego, CA, USA) are well-characterized MEK1/2 inhibitors (Davies et al., 2000) . Akt inhibitor III (Calbiochem) is a phosphatidylinositol analog capable of suppressing Akt phosphorylation. The mTOR inhibitor rapamycin was obtained from Cell Signaling Technology (Danvers, MA, USA).
Western blot
The cells were washed in phosphate-buffered saline (PBS), centrifuged and lysed in radioimmunoprecipitation assay buffer supplemented with 0.5 mM phenylmethylsulfonyl fluoride, phosphatase inhibitor cocktails I and II from Sigma (St Louis, MO, USA) and protease inhibitor cocktail from Roche (Basel, Switzerland) as described previously (Marzec et al., , 2007 Wlodarski et al., 2005) . For normalization of gel loading, the protein extracts were assayed using the Lowry method (Bio-Rad, Hercules, CA, USA) Dc protein assay). Typically, 5-50 mg of the protein per lane was loaded. To examine protein phosphorylation, the membranes were incubated with antibodies specific for Akt T308, TSC2 S939, S6rp S235/236, 4E-BP1 T37/46, ERK1/2 T202/Y204, STAT3 S727 or NPM/ALK Y664 (all from Cell Signaling). To detect the total protein, we used anti-ERK1/2 and -S6rp antibodies (both from Cell Signaling) and anti-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Next, the membranes were incubated with the appropriate secondary, peroxidaseconjugated antibodies. The blots were developed using the ECL Plus System from Amersham.
Immunoprecipitation
Cells lysates were precipitated with TSC2 rabbit antibody (Santa Cruz) and 20 ml Protein G agarose (Gibco BRL, Carlsbad, CA, USA) was performed for 2 h at 41C. The immunoprecipitates were washed, boiled, suspended in reducing sodium dodecyl sulfate (SDS) loading buffer, separated on a 9% polyacrylamide/SDS gel and transferred electrophoretically onto hybridization transfer membranes. The membranes were blocked with 5% milk in Tris-buffered saline with 0.1% Tween buffer for 30 min and incubated overnight with the primary antibody, washed and incubated with peroxidaseconjugated secondary antibody.
Immunohistochemical analysis
Formalin-fixed paraffin-embedded tissue specimens of 12 cases of ALK þ TCL were deparaffinized and heat induced for antigen retrieval by boiling slides in 10 mM citrate buffer, pH 6, for 20 min. The sections were blocked for 10 min with peroxidase blocking system and incubated at RT with antiphospho-S6rp(S235/236), -4E-BP1(S65) and anti-ALK (Dako, Glostrup, Denmark) primary antibody at 1:50 dilution for 90 min, secondary biotinylated anti-rabbit IgG for 30 min and the streptavidin-biotinylated horseradish peroxidase complex for 30 min. The slides were stained with DABplus (Dako) for 5 min and counterstained with hematoxylin.
siRNA assay ALK-, ERK1-or ERK2-specific siRNA or nonsense siRNA (Dharmacon, Lafayette, CO, USA) were introduced into cells at 100 nM using 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE-C) lipofectamine (Invitrogen, Carlsbad, CA, USA). The procedure was repeated after 24 h and cells were harvested 24 h (for ERK 1 and 2) or 48 h (ALK) later.
BrdU incorporation assay
The incorporation was determined using a commercially available Cell Proliferation ELISA kit (Roche) as described . In brief, cells were seeded in 96-well plates (Corning) at 1 Â 10 4 cells/well in complete Roswell Park Memorial Institute (RPMI) 1640/10% FBS medium for 20-24 h and labeled with 5-bromo-2 0 -deoxyuridine (BrdU) for an additional 4 h. After plate centrifugation, supernatant removal and plate drying, the cells were fixed and the DNA was denaturated in 200 ml FixDenat. The amount of incorporated BrdU was determined by the addition of antibody-peroxidase conjugate followed by substrate colorimetric conversion of the substrate.
Terminal deoxy transferase uridine triphosphate nick end-labelling assay Cell apoptosis was determined in the ApoAlert DNA Fragmentation assay kit (BD Bioscience, San Jose, CA, USA) as described . In brief, after culture at 0.5 Â 10 6 cells/ml, cells were collected, fixed with 1% formaldehyde/PBS, permeabilized with 70% ice-cold ethanol for at least 2 h and incubated in TdT incubation buffer for 1 h at 371C. The reaction was stopped by the addition of 20 mM ethylenediaminetetraacetic acid and the samples were resuspended in PI/RNAse/PBS and analysed by flow cytometry (BD FACSCalibur Flow Cytometer, BD Bioscience).
